Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105921 | 0.90 | PKM (0.51) | TACR1RORCMAPTPKM | |
| SCHEMBL2240106 | 0.90 | TACR1 (0.58) | TACR1RORCMAPTPKMSLC6A3 | |
| SCHEMBL4004318 | 0.90 | PKM (0.51) | TACR1RORCMAPTPKM | |
| SCHEMBL7904145 | 0.90 | PKM (0.51) | TACR1RORCMAPTPKM | |
| SCHEMBL4790687 | 0.90 | TACR1 (0.58) | TACR1RORCMAPTPKMSLC6A3 | |
| SCHEMBL3004868 | 0.90 | PKM (0.51) | TACR1RORCMAPTPKM | |
| SCHEMBL1105755 | 0.90 | PKM (0.51) | TACR1RORCMAPTPKM | |
| SCHEMBL3010603 | 0.90 | PKM (0.51) | TACR1RORCMAPTPKM | |
| SCHEMBL12647197 | 0.90 | TACR1 (0.58) | TACR1RORCMAPTPKMSLC6A3 | |
| SCHEMBL23060617 | 0.87 | PDE4B (0.59) | TACR1RORCPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138423-B2 | Diseases mediated by tachykinins and for seritonin reuptake transporter protein as reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| WO-2006014665-A2 | ARYLPYRROLIDINE DERIVATIVES AS NK-1/SSRI ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060020011-A1 | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists | BRISTOL-MEYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020011-A1 | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists | TPH1, SLC6A4, HTR1D | TACR1 24/4885RORC 3001/4885PDE4B 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.